Cidara Touts Positive Phase II Antifungal Data
Cidara Therapeutics reported its mid-stage antifungal candidate hit its primary endpoints and is on track to begin Phase III testing later this year. Source: BioSpace
Cidara Therapeutics reported its mid-stage antifungal candidate hit its primary endpoints and is on track to begin Phase III testing later this year. Source: BioSpace
In the world of politics and civil rights, the ideas of gender and transgender have been a hot-button issue. But a new study suggests that transgender people may have a…
Here are six biotech companies that should benefit the most from research-and-development spending trends that are expected to stimulate biotech development. Source: BioSpace
Arbor Biotechnologies came out of stealth mode yesterday with a $15.6 million Series A financing round. Source: BioSpace
There are dangers in biotech funding and Theranos should serve as a warning. Source: BioSpace
Tetra Discovery Partners announced that the FDA had given its Investigational New Drug application the go-ahead for Fragile X Syndrome and potentially other autism spectrum disorders. Source: BioSpace
Peggy Whitson has spent 665 days in space, more than any other US astronaut and more than any other female astronaut in the world. You don’t associate Peggy Whitson with…
Platinum Equity submitted a binding offer to Johnson & Johnson to buy LifeScan for $2.1 billion. Source: BioSpace
AMO Pharma reported that patients treated with its Phase II neuromuscular treatment for onset myotonic dystrophy type 1 experienced clinical benefits such as an improvement in cognitive function and an…
Adaptimmune reported it saw three partial responses in three of the four myxoid/ round cell liposarcoma (MRCLS) patients the company dosed with its NY-ESO SPEAR T-cells. Source: BioSpace